Early prediction of lenvatinib treatment efficacy by using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study

INTRODUCTION: Lenvatinib, an oral molecular targeted drug, is used to treat patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment. Effective methods for evaluating molecular targeted drugs are a critical unmet need owing to their expensive costs and uni...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Satoshi, Shiga, Tohru, Hirata, Kenji, Taguchi, Jun, Magota, Keiichi, Ariga, Shin, Gouda, Tomohiro, Ohhara, Yoshihito, Homma, Rio, Shimizu, Yasushi, Kinoshita, Ichiro, Tsuji, Yasushi, Homma, Akihiro, Iijima, Hiroaki, Tamaki, Nagara, Dosaka-Akita, Hirotoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119439/
https://www.ncbi.nlm.nih.gov/pubmed/30166292
http://dx.doi.org/10.1136/bmjopen-2017-021001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119439/
https://www.ncbi.nlm.nih.gov/pubmed/30166292
http://dx.doi.org/10.1136/bmjopen-2017-021001

Ejemplares similares